M
Marta Nyakas
Researcher at Oslo University Hospital
Publications - 58
Citations - 5426
Marta Nyakas is an academic researcher from Oslo University Hospital. The author has contributed to research in topics: Melanoma & Dabrafenib. The author has an hindex of 18, co-authored 49 publications receiving 4216 citations. Previous affiliations of Marta Nyakas include Tel Aviv University & University of Oslo.
Papers
More filters
Journal ArticleDOI
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty,Caroline Robert,Peter Hersey,Paul C. Nathan,Claus Garbe,Mohammed M. Milhem,Lev V. Demidov,Jessica C. Hassel,Piotr Rutkowski,Peter Mohr,Reinhard Dummer,Uwe Trefzer,James Larkin,Jochen Utikal,Brigitte Dréno,Marta Nyakas,Mark R. Middleton,Juergen C. Becker,Michelle Casey,Laurie Sherman,Frank S. Wu,Daniele Ouellet,Anne-Marie Martin,Kiran Patel,Dirk Schadendorf +24 more
TL;DR: Tametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.
Journal ArticleDOI
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V. Long,A. Hauschild,M. Santinami,Victoria Atkinson,M. Mandal,Vanna Chiarion-Sileni,James Larkin,Marta Nyakas,Caroline Dutriaux,Andrew Haydon,Caroline Robert,Laurent Mortier,Jacob Schachter,Dirk Schadendorf,Thierry Lesimple,Ruth Plummer,R. Ji,Ping Zhang,Bijoyesh Mookerjee,Jeffrey J. Legos,Richard F. Kefford,Reinhard Dummer,John M. Kirkwood +22 more
TL;DR: Adjuvant use of combination therapy with dabrafenib plus trametinib resulted in a significantly lower risk of recurrence in patients with stage III melanoma with BRAF V600E or V600K mutations than the adjuvantUse of placebo and was not associated with new toxic effects.
Journal ArticleDOI
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto,Michele Del Vecchio,Caroline Robert,Andrzej Mackiewicz,Vanna Chiarion-Sileni,Ana Arance,Céleste Lebbé,Lars Bastholt,Omid Hamid,Piotr Rutkowski,Catriona M. McNeil,Claus Garbe,Carmen Loquai,Brigitte Dréno,Luc Thomas,Jean-Jacques Grob,Gabriella Liszkay,Marta Nyakas,Ralf Gutzmer,Joanna Pikiel,Florent Grange,Christoph Hoeller,Virginia Ferraresi,Michael Smylie,Dirk Schadendorf,Laurent Mortier,Inge Marie Svane,Delphine Hennicken,Anila Qureshi,Michele Maio +29 more
TL;DR: In patients with advanced melanoma, ipilimumab 10 mg/kg resulted in significantly longer overall survival, but with increased treatment-related adverse events, while the treatment landscape for advanced melanomas has changed since this study was initiated.
Journal ArticleDOI
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma.
Einar O. Vik-Mo,Marta Nyakas,Birthe Viftrup Mikkelsen,Birthe Viftrup Mikkelsen,Morten C. Moe,Paulina Due-Tönnesen,Else Marit Inderberg Suso,Stein Sæbøe-Larssen,Cecilie Sandberg,Cecilie Sandberg,Jan E. Brinchmann,Eirik Helseth,Anne Marie Rasmussen,Knut Lote,Steinar Aamdal,Gustav Gaudernack,Gunnar Kvalheim,Iver A. Langmoen +17 more
TL;DR: These findings suggest that vaccination against glioblastoma stem cells is safe, well-tolerated, and may prolong progression-free survival.
Journal ArticleDOI
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
R. Dummer,Axel Hauschild,Mario Santinami,Victoria Atkinson,Mario Mandalà,John M. Kirkwood,Vanna Chiarion Sileni,James Larkin,Marta Nyakas,C. Dutriaux,Andrew M. Haydon,Caroline Robert,Laurent Mortier,Jacob Schachter,Thierry Lesimple,Ruth Plummer,Kohinoor Dasgupta,Eduard Gasal,Monique Tan,Georgina V. Long,Dirk Schadendorf +20 more
TL;DR: In the 5-year follow-up of a phase 3 trial involving patients who had resected stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant therapy with dabrafenib plus trametinib resulted in a longer duration of survival without relapse or distant metastasis than placebo with no apparent long-term toxic effects.